Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update
November 05 2020 - 09:00AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
(“Adamis”) announced today that it will host an investor conference
call on Monday, November 9, 2020 at 2:00 pm Pacific
Time to discuss its financial and operating results for the
third quarter of 2020 as well as provide an update on business
developments and activities. The company’s press release
concerning its third quarter 2020 financial results will be
available after 1:00 p.m. Pacific Time on November
9, 2020, on its website at www.adamispharmaceuticals.com, and
the company also expects to file its quarterly report on Form 10-Q
for the third quarter ended September 30, 2020, on that
date.
Event: Adamis Pharmaceuticals Third
Quarter 2020 Conference CallDate: Monday,
November 9, 2020Time: 2:00 pm PT (5:00
pm ET)US Dial-in (Toll
Free): 1-855-327-6838TOLL/International
Dial-in: 1-604-235-2082Conference
ID: 10011804
Dr. Dennis J. Carlo, President and CEO of Adamis, will host
the call along with other members of the management team. The
call is open to the public and will provide an update on recent
developments, events that have taken place during this quarter and
certain target milestones and goals for future periods.
Forward-looking statements concerning expectations regarding future
company performance may be made during the conference call.
A live audio webcast of the conference call will also be
available via this link –
http://public.viavid.com/index.php?id=142367.
Participants should access this webcast site 10 minutes
before the start of the call. In addition, a telephone playback of
the call will be available after approximately 5:00 pm
PT on November 9, 2020. To listen to the replay,
call toll free 1-844-512-2921 within the United States or
1-412-317-6671 when calling internationally (toll). Please use the
replay PIN number 10011804.
About Adamis
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
company’s SYMJEPI (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. Adamis’ naloxone injection
product candidate, ZIMHI, for the treatment of opioid overdose is
currently under FDA review with a target action date of November
15, 2020. Adamis is developing additional products, including
treatments for acute respiratory diseases, such as COVID-19,
influenza, asthma and COPD. The company’s subsidiary, U.S.
Compounding, Inc., compounds sterile prescription drugs, and
certain nonsterile drugs for human and veterinary use by hospitals,
clinics, surgery centers, and vet clinics throughout most of the
United States.
ContactMark FlatherSenior Director, Investor
Relations& Corporate CommunicationsAdamis Pharmaceuticals
Corporation(858) 412-7951mflather@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2023 to Mar 2024